Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BU3L
|
|||
| Drug Name |
Pyrrolidine derivative 13
|
|||
| Synonyms |
PMID28906174-Compound-Figure1f
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Obseva SA
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxytocin receptor (OTR) | Target Info | Antagonist | [1] |
| Vasopressin V1a receptor (V1AR) | Target Info | Antagonist | [1] | |
| Target's Patent Info | Oxytocin receptor (OTR) | Target's Patent Info | [1] | |
| Vasopressin V1a receptor (V1AR) | Target's Patent Info | [1] | ||
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| cAMP signaling pathway | ||||
| Oxytocin signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Oxytocin receptor mediated signaling pathway | |||
| Reactome | Vasopressin-like receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Myometrial Relaxation and Contraction Pathways | ||||
| Oxytocin signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.